The stock of Genmab ADR (NASDAQ: GMAB) has decreased by -3.11 when compared to last closing price of 19.93. Despite this, the company has experienced a -5.44% fall in its stock price over the last five trading sessions. globenewswire.com reported 2025-05-12 that Company Announcement COPENHAGEN, Denmark; May 12, 2025 – Genmab A/S (Nasdaq: GMAB). On March 25, 2025, Genmab announced the initiation of a share buy-back program to repurchase up to 2.2 million shares to reduce capital and to honor our commitments under the Restricted Stock Unit program.
Is It Worth Investing in Genmab ADR (NASDAQ: GMAB) Right Now?
The price-to-earnings ratio for Genmab ADR (NASDAQ: GMAB) is above average at 10.95x. The 36-month beta value for GMAB is also noteworthy at 0.95. There are mixed opinions on the stock, with 4 analysts rating it as a “buy,” 1 rating it as “overweight,” 4 rating it as “hold,” and 0 rating it as “sell.”
The public float for GMAB is 614.73M, and at present, short sellers hold a 0.39% of that float. The average trading volume of GMAB on May 14, 2025 was 1.55M shares.
GMAB’s Market Performance
GMAB’s stock has seen a -5.44% decrease for the week, with a 2.66% rise in the past month and a 2.22% gain in the past quarter. The volatility ratio for the week is 3.21%, and the volatility levels for the past 30 days are at 2.29% for Genmab ADR The simple moving average for the past 20 days is -4.94% for GMAB’s stock, with a -14.00% simple moving average for the past 200 days.
Analysts’ Opinion of GMAB
Leerink Partners gave a rating of “Outperform” to GMAB, setting the target price at $27 in the report published on February 13th of the current year.
GMAB Trading at -4.33% from the 50-Day Moving Average
After a stumble in the market that brought GMAB to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -36.50% of loss for the given period.
Volatility was left at 2.29%, however, over the last 30 days, the volatility rate increased by 3.21%, as shares sank -0.05% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -15.90% lower at present.
During the last 5 trading sessions, GMAB fell by -5.44%, which changed the moving average for the period of 200-days by -31.35% in comparison to the 20-day moving average, which settled at $20.31. In addition, Genmab ADR saw -7.47% in overturn over a single year, with a tendency to cut further losses.
Stock Fundamentals for GMAB
Current profitability levels for the company are sitting at:
- 0.31 for the present operating margin
- 0.95 for the gross margin
The net margin for Genmab ADR stands at 0.36. The total capital return value is set at 0.17. Equity return is now at value 22.69, with 19.07 for asset returns.
Based on Genmab ADR (GMAB), the company’s capital structure generated 0.03 points at debt to capital in total, while cash flow to debt ratio is standing at 7.55. The debt to equity ratio resting at 0.03. The interest coverage ratio of the stock is 68.4.
Currently, EBITDA for the company is 7.39 billion with net debt to EBITDA at -1.09. When we switch over and look at the enterprise to sales, we see a ratio of 3.22. The receivables turnover for the company is 3.22for trailing twelve months and the total asset turnover is 0.47. The liquidity ratio also appears to be rather interesting for investors as it stands at 5.34.
Conclusion
In summary, Genmab ADR (GMAB) has had a mixed performance as of late. Analysts have mixed opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
